DZD Multicenter Studies Can be Continued Under Certain Conditions

The general interruption of the clinical studies of the German Center for Diabetes Research (DZD) as part of the precautionary measures relating to the coronavirus will end on April 27. The study teams at most sites will gradually resume operations as far as local regulations permit.

However, individual studies that pose a particular risk will continue to be dispensed with for the safety of all concerned.

If you are participating in one of the DZD studies and have questions, you are welcome to contact representatives of the study team at your study centers by telephone. Please use the telephone numbers listed for the respective studies.

Well-adjusted blood sugar levels and no concomitant or secondary diseases are the best protection against a severe course of COVID-19 for people with diabetes. However, if one or more diabetes-related concomitant and secondary diseases such as cardiovascular disease or organ damage are present, the risk of a severe course of COVID-19 is increased. The German Diabetes Society (DDG) advises these persons to be particularly careful: large crowds, public transport and regions with known SARS-CoV-2 infections should be avoided due to the increased risk of infection.

Further information on the coronavirus and diabetes can also be found on the national diabetes information portal

Detailed information from DDG

Further information on the DZD multicenter studies.